I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.
The impressive impact of strength training for preserving muscle mass while taking a GLP-1 drug for obesity, as seen in randomized trial @NatureMedicine
T=tirzepatide alone (Zepbound), T + REx=drug with resistance exercise
https://t.co/yLDvQ1lo5z
The funny thing is that Perplexity is primarily using Anthropic models for our use cases, but Anthropic sucks at product, and they're not really receptive to any feedback on their product
Same with OpenAI
The first randomized trial of resistance training on tirzepatide is here.
Researchers in Western Australia put 120 adults between 50 and 70 on tirzepatide for 40 weeks.
Half of them lifted weights three times a week, and the other half went about their normal lives. At the end, both groups had lost almost exactly the same amount of weight, roughly 22 kilograms each.
The group that lifted lost 25% less lean tissue.
Their strength went up 10 to 18%. The group that didn’t lift got 6 to 9% weaker over the same stretch.
To be fair, lifting reduced lean loss but didn’t eliminate it. The training was supervised, attendance was 91%, and most people won’t hit that on their own.
At the end of the day, Tirzepatide is a remarkable tool for taking fat off the body. However, a tool only does what it was built to do, and protecting your muscle was never its job.
That part falls on you!
Three days a week under a bar. Consider it part of the prescription.
AWS CEO:
AI INFERENCE ISN'T EVEN AT 1% OF WHAT IT WILL BECOME
AWS CEO Matt Garman, speaking on @alexeheath podcast: "Every time we see inference get, you know, 50% cheaper, we see an order of magnitude more usage."
Yet revenue keeps rising even as inference gets cheaper.